Key Points
- Moderna CFO James Mock sold 34,836 shares for approximately $4.69 million at an average price of $134.49, reducing his direct ownership by about 37%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan.
- Moderna reported a quarterly loss of $1.97 per share, narrowly beating estimates, while revenue of $145 million exceeded expectations and increased 2.1% year over year. Analysts expect the company to post a full-year loss of $6.09 per share.
- Institutional investors hold 75.33% of Moderna’s shares, while Wall Street’s consensus rating remains “Hold” with an average price target of $76.72.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) CFO James Mock sold 34,836 shares of the firm's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Moderna Trading Up 1.9%
Shares of NASDAQ:MRNA opened at $146.69 on Tuesday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66. The business has a 50 day moving average of $93.65 and a two-hundred day moving average of $67.53. The company has a market capitalization of $58.56 billion, a PE ratio of -18.36 and a beta of 1.10.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the firm earned ($2.13) EPS. The business's quarterly revenue was up 2.1% on a year-over-year basis. As a group, analysts forecast that Moderna, Inc. will post -6.09 EPS for the current year.
Hedge Funds Weigh In On Moderna
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRNA. BlackRock Inc. acquired a new position in shares of Moderna during the 2nd quarter worth about $2,142,877,000. California State Teachers Retirement System lifted its stake in Moderna by 6,698.1% in the 2nd quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company's stock valued at $1,938,523,000 after buying an additional 27,274,128 shares in the last quarter. Theleme Partners LLP acquired a new stake in Moderna in the 2nd quarter worth about $564,272,000. Capital World Investors acquired a new stake in Moderna in the 4th quarter worth about $378,299,000. Finally, Wellington Management Group LLP increased its stake in Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company's stock worth $172,384,000 after buying an additional 103,977 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.
Moderna News Summary
Here are the key news stories impacting Moderna this week:
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. Piper Sandler reiterated an "overweight" rating on shares of Moderna in a research report on Monday, August 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Moderna in a research report on Wednesday, September 9th. Royal Bank Of Canada restated a "sector perform" rating and issued a $130.00 price target on shares of Moderna in a research note on Wednesday, August 19th. The Goldman Sachs Group upped their price target on Moderna from $67.00 to $120.00 and gave the stock a "neutral" rating in a report on Wednesday, August 19th. Finally, Loop Capital set a $135.00 price target on Moderna in a research report on Wednesday, August 19th. Seven equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, Moderna presently has a consensus rating of "Hold" and a consensus price target of $76.72.
Check Out Our Latest Analysis on Moderna
About Moderna
(
Get Free Report)
Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.
The company's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.
Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
